Bioactive Materials for Biomedical Applications

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biopharmaceutics".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 1262

Special Issue Editors

Protein Research Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab City, Alexandria P.O. Box 21934, Egypt
Interests: polymers; wound dressings; antimicrobials; antioxidants; anti-inflammatory; hydrogels; chitosan; hyaluronan; keratinase; lipase; ubiquitin; posttranslational modification; nanoparticles; oxidative stress; mitochondrial dysfunction; oxidative damages
Special Issues, Collections and Topics in MDPI journals
Polymer Materials Research Department, Advanced Technologies, and New Materials Research Institute (ATNMRI), City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab City, Alexandria P.O. Box 21934, Egypt
Interests: natural polymer; biomedical; pharmaceutical and environmental applications; antimicrobial polymers; polysaccharide; proteins; RO membrane
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Traditional materials are thought to lack intrinsic biological activities, hindering their use in the medical field. Therefore, the application of bioactive materials has been receiving considerable interest due to their potential implications for the diagnosis of human diseases and the treatment of several chronic diseases. Bioactive materials are next-generation biomaterials that interact with a variety of cells and tissues from living organisms. In this context, innovative bioactive materials with outstanding properties that may be utilized in several biomedical applications are motivating research on either the functionalization of materials or the integration of bioactive compounds into these materials to impart them with the desired activity. Furthermore, given their particular traits, the functionalization of materials is pivotal in devising new materials to secure unmet requisites; for instance, new stents and other cardiovascular requirements, active scaffolds for supporting the bones, or materials to promote wound healing. Moreover, smart bioactive materials are fabricated, including materials with new properties that can be used for drug delivery systems and intelligent medical materials.

Dr. Mohamed A. Hassan
Dr. Tamer M. Tamer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioactive materials-derived nature
  • synthesis and characterization of biomedical materials
  • functionalized materials
  • in vitro/in vivo studies of biomedical materials
  • tissue engineering and wound healing
  • implantable biomedical materials
  • drug delivery systems and pharmacokinetic studies
  • bioactive gels and composites
  • thermo-responsive materials
  • nanocomposites

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3036 KiB  
Article
Silk Fibroin-Modified Liposome/Gene Editing System Knocks out the PLK1 Gene to Suppress the Growth of Lung Cancer Cells
by Peng Pan, Xueping Liu, Mengqi Fang, Shanlong Yang, Yadong Zhang, Mingzhong Li and Yu Liu
Pharmaceutics 2023, 15(12), 2756; https://doi.org/10.3390/pharmaceutics15122756 - 12 Dec 2023
Cited by 1 | Viewed by 928
Abstract
Polo-like protein kinase 1 (PLK1) plays a key role in lung cancer cell mitosis. The knockout of PLK1 gene by the CRISPR–Cas9 system can effectively inhibit the proliferation of tumor cells, but there is no suitable vector for in vivo delivery. In this [...] Read more.
Polo-like protein kinase 1 (PLK1) plays a key role in lung cancer cell mitosis. The knockout of PLK1 gene by the CRISPR–Cas9 system can effectively inhibit the proliferation of tumor cells, but there is no suitable vector for in vivo delivery. In this study, CRISPR–Cas9 gene knockout plasmids encoding sgRNA, Cas9 and green fluorescent protein were constructed. Then, the plasmids were packaged with liposome (Lip) and cholesterol-modified Antheraea pernyi silk fibroin (CASF) to obtain the CASF/Lip/pDNA ternary complex. The CASF/Lip/pDNA complex was transfected into lung cancer cells A549 to investigate the transfection efficiency, the PLK1 gene knockout effect and the inhibitory effect on lung cancer cells. The results showed that the transfection efficiency of the CASF/Lip/pDNA complex was significantly higher than that of the Lip/pDNA binary complex, and the expression of PLK1 in cells transfected with CASF/Lip/pDNA complexes was significantly lower than that in cells transfected with Lip/pDNA complexes. The CASF/Lip/pDNA complex significantly increased the apoptosis rate and decreased the proliferation activity of lung cancer cells compared with Lip/pDNA complexes. The cytotoxicity of the complexes was evaluated by coculture with the human bronchial epithelial cells BEAS2B. The results showed that CASF/Lip/pDNA complexes exhibited lower cytotoxicity than Lip/pDNA complexes. The fibroin-modified liposome/PLK1 gene knockout system not only effectively inhibited the growth of lung cancer cells but also showed no obvious toxicity to normal cells, showing potential for clinical application in lung cancer therapy. Full article
(This article belongs to the Special Issue Bioactive Materials for Biomedical Applications)
Show Figures

Graphical abstract

Back to TopTop